{"text": "c-erbB-2 overexpression detected using immunohistochemistry is observed in 17.9% of patients with SCLC and has statistically significant prognostic value. Our findings suggest that c-erbB-2 may be a potential target for site-specific immunotherapy in SCLC.", "denotations": [{"id": "T1", "obj": "gene", "span": {"begin": 0, "end": 8}}, {"id": "T2", "obj": "disease", "span": {"begin": 98, "end": 102}}]}
